MYRIAD GENETICS THIRD QUARTER 2026 FINANCIAL EARNINGS - MYRIAD GENETICS INC

Explicit Guidance:

• Full-Year 2026 Revenue: Raised midpoint to $785 million (range: $780–$790 million). This reflects Q3 outperformance and revised assumptions for HCT average revenue per test, partially offset by anticipated softness in prenatal volume due to the divestiture announcement.
• 2026 Segment Guidance (Implicit): Provided separate outlooks for Hereditary Cancer Testing (HCT) and Mental Health (combined Cancer Care & Mental Health) and Prenatal Health.
• HCT Average Revenue Per Test (ASP): Expect modest headwinds in the medium-to-long term, averaging a decline of 1% to 5% annually (skewing 3% to 4% in recent years), though specific years may vary (e.g., flat or >5% decline).
• 2027 Profitability Outlook: Management expects "meaningful progress" in bottom-line profitability in 2027, driven by the post-divestiture portfolio, ASCEND initiative, and ASP initiatives, though specific quantitative guidance is deferred until 2027 planning is complete.
• Precise MRD Reimbursement Timeline:
  • Breast Cancer: Expect reimbursement submissions to CMS in Summer 2026, with coverage beginning first half of 2027.
  • Colorectal & Renal Cancer: Expect reimbursement submissions later in 2027.
• Divestiture Proceeds: All-cash transaction valued at $210 million plus inventory (total ~$215M+), expected to strengthen balance sheet for debt reduction, internal/external growth investments, and general corporate purposes.

Business-Segment Outlook:

• Cancer Care Continuum:
  • Volume: Driven by guideline expansions (NCCN) for multi-gene panel testing in endometrial, colorectal, and gastric cancers; HCT volume growth of 6% YoY in Q3 with record highs in unaffected population testing.
  • Prostate (Prolaris Plus AI): Positive feedback post-relaunch, though volume impacted by NCCM guidelines recommending blood-based biomarkers prior to biopsy.
  • Precise MRD: Interim data shows 91% recurrence detection sensitivity (higher than peer assays); early access sites active; testing demand managed prudently until reimbursement established.
• Mental Health (GeneSight): Steady volume growth of 3% YoY in Q3; ordering provider base expanded to 40,000+ clinicians; disciplined capital efficiency maintained.
• Prenatal Health: Revenue to decline as volume shifts to LabCorp; transaction targets preservation of patient access for remaining providers; ~500 employees transitioning to LabCorp.
• Financial Profile Post-Deal: Anticipated >100 basis points improvement in revenue growth rate and >500 basis points improvement in gross margins post-divestiture compared to current state.

Market and Competitive Outlook:

• Reimbursement Environment: Continued "modest headwinds" on HCT ASP driven by increased "zero-pay" rates and claim denials due to payer P&L management and prior authorization requirements, rather than explicit contract rate reductions.
• Competitive Positioning: Myriad views current ASP pressures as an industry-wide trend affecting mature tests; leveraging "MyRisk reimbursement initiative" and peer engagement to navigate complex payer policies.
• Demand Trends: Strong underlying demand for cancer and mental health tests; prenatal demand softening due to market dynamics and strategic pivot.

Macro / Industry Outlook:

• Guideline Impact: Continued expansion of clinical guidelines (NCCN) expected to support long-term volume growth in hereditary cancer testing across colorectal, endometrial, and gastric cancer populations.
• Payer Behavior: Anticipated continued scrutiny on specialty diagnostics spend leading to increased denials and friction, requiring active revenue cycle management.

Strategic Initiatives:

• Prenatal Divestiture: Definitive agreement signed to sell prenatal business to LabCorp for $210 million + inventory; transaction expected to sharpen focus on cancer care continuum and unlock shareholder value.
• ASCEND Initiative: Multi-year operational modernization to improve efficiency, productivity, and cost structure via optimized processes, organizational design, and new tools; benefits expected to layer in throughout 2027.
• Revenue Cycle & Access: Launching "pair-by-pair market access strategy" focusing on policy engagement, LBM collaboration, and AI-enabled workflow acceleration to reduce reimbursement friction.
• Product Portfolio: Rigorous review completed to maximize shareholder value; focus narrowed to high-margin, high-growth cancer care continuum.

Risks and Headwinds to Outlook:

• Reimbursement Friction: Persistent risk of zero-pay rates and denials impacting ASP; "more work to do" remains in revenue cycle optimization.
• Clinical Guideline Changes: NCCM guidelines recommending blood-based testing prior to biopsy may impact Proaris volume.
• Transaction Execution: Risk of disruption during the prenatal business transition to LabCorp, though management expects a smooth handover preserving patient access.
• Market Volatility: Potential for ASP declines to exceed the 1-5% average range in specific years (e.g., >5% decline or flat).

Management Tone on the Future:

• Confidence: "Energized" and "pleased" with the strategic direction; confidence in the "materially stronger financial profile" post-divestiture.
• Hedging: Conservative assumptions applied to prenatal volume in 2026 guidance; PRD reimbursement timing framed as "early access" with managed demand until coverage is established.
• Strategic Clarity: Shift from "softness" narrative to "decisive action" and "execution," emphasizing a focused, profitable future on the cancer care continuum.

Miscellaneous:

• Capital Resources: Ended Q3 2026 with $182 million in available capital, providing flexibility for the announced deal and future investments.
• Leadership: Vishal Sikri promoted to Executive Vice President of Commercial; Mark Verratti (COO) joining Q&A (transcript notes "Mark Berati" in one instance but clarifies Verratti is COO).
• Data Readouts: Additional Precise MRD data readouts and publications expected in 2027.